Two patient populations were evaluated regarding the monitoring of aminoglycoside serum concentrations by either a pharmacokinetic service (PKS) or staff physicians. Both groups were evenly matched by demographic characteristics, underlying disease state(s), and indication for aminoglycoside therapy. Patients in the PKS group showed increased incidence of clinical improvement after therapy when compared with the physicians' group; a decreased length of stay and duration of treatment were also observed in this group. Aminoglycoside dosing and monitoring by the PKS provided an estimated average cost savings of $491,00 per patient. The results indicate that the PKS may provide cost savings and benefit in aminoglycoside monitoring for the patient and/or the hospital.
|Original language||English (US)|
|Pages (from-to)||92-99, 102|
|State||Published - Jan 1 1987|
ASJC Scopus subject areas
- Pharmaceutical Science